Bicillin L-a
NDC Package 50090-1666-0

11-digit billing NDC: 50090166600

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Bicillin L-a is to reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-1666 and is authorized under FDA application NDA050141.

Identification & Billing

NDC Package Code
50090-1666-0
Package Description
10 SYRINGE in 1 PACKAGE / 1 mL in 1 SYRINGE
Product Code
11-Digit Billing Format
50090166600
RxNorm Crosswalk
  • RxCUI: 731564 - penicillin G benzathine 600,000 UNT in 1 ML Prefilled Syringe
  • RxCUI: 731564 - 1 ML penicillin G benzathine 600000 UNT/ML Prefilled Syringe
  • RxCUI: 731564 - penicillin G benzathine 600,000 UNT per 1 ML Prefilled Syringe
  • RxCUI: 731566 - BICILLIN L-A 600,000 UNT in 1 ML Prefilled Syringe
  • RxCUI: 731566 - 1 ML penicillin G benzathine 600000 UNT/ML Prefilled Syringe [Bicillin L-A]

Clinical Specifications

Proprietary Name
Bicillin L-a
Dosage Form
-
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine:Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci.Venereal infections—Syphilis, yaws, bejel, and pinta.Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis:Rheumatic fever and/or chorea—Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
FDA Application #
NDA050141
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-27-1952
End Marketing Date
12-31-2022
Listing Expiration
12-31-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-1666-0 identifies a specific commercial package of 10 syringe in 1 package / 1 ml in 1 syringe of Bicillin L-a, labeled by A-s Medication Solutions. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by A-s Medication Solutions on June 27, 1952. The current certification is valid through December 31, 2022.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090166600. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-1666-0
11-Digit CMS (5-4-2)
50090-1666-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.